Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

August 16, 2012

USA v. Regenerative Sciences, LLC, et al

Track this case

Case Number:

12-5254

Court:

Appellate - DC Circuit

Nature of Suit:

1890 Other Statutory Actions

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 04, 2014

    FDA Can Regulate Stem Cell Treatments, DC Circ. Rules

    The D.C. Circuit on Tuesday ruled that Regenerative Sciences LLC's stem cell treatment is a drug and therefore subject to U.S. Food and Drug Administration regulations, rejecting the company's claims that its process is a medical procedure subject to state laws.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login